{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,26]],"date-time":"2026-10-26T19:56:47Z","timestamp":1793044607952,"version":"4.5.0"},"reference-count":37,"publisher":"Oxford University Press (OUP)","issue":"9","license":[{"start":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T00:00:00Z","timestamp":1788220800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/academic.oup.com\/pages\/standard-publication-reuse-rights"}],"funder":[{"DOI":"10.13039\/501100003130","name":"Research Foundation Flanders","doi-asserted-by":"publisher","award":["FWO\u201412A3026N"],"award-info":[{"award-number":["FWO\u201412A3026N"]}],"id":[{"id":"10.13039\/501100003130","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2026,9,3]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background and Aims<\/jats:title>\n                    <jats:p>Translational attrition remains a major obstacle in inflammatory bowel disease (IBD) drug development due to limited concordance between conventional preclinical models and patient responses. In this study we aimed to evaluate the activity of the selective salt-inducible kinase 2\/3 (SIK2\/3) inhibitor GLPG3970 across complementary experimental platforms, including murine colitis, patient-derived intestinal organoids, and ex vivo mucosal biopsies, and compared these findings with transcriptional data from a UC-phase 2 study.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>Therapeutic efficacy of GLPG3970 (20\u2009mg\/kg) was assessed in the murine CD4\u2009+\u2009CD25\u2212 T-cell transfer colitis model. Epithelial-intrinsic responses were investigated in ulcerative colitis (UC) patient-derived intestinal organoids (n\u2009=\u20095). In parallel, mucosal biopsies from UC (n\u2009=\u200910) and Crohn\u2019s disease (CD; n\u2009=\u200910) patients were treated ex vivo with GLPG3970 (60\u2009\u00b5M) or tofacitinib (10\u2009\u00b5M) for 24\u2009h. Treatment-induced transcriptional signatures were compared with bulk RNA sequencing data from patients enrolled in a short 6-week UC-phase 2 study (GLPG3970 n\u2009=\u200921, placebo n\u2009=\u200910; NCT04577794).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>GLPG3970 reduced disease activity and restored goblet cell-associated mucus production in the T-cell transfer model. In patient-derived intestinal organoids, SIK2\/SIK3 inhibition enhanced epithelial mucus secretion. Ex vivo exposure of IBD biopsies elicited anti-inflammatory transcriptional and proteomic responses, revealing disease- and treatment-specific signatures. Notably, GLPG3970-induced signatures in ex vivo biopsies closely aligned with treatment-responsive gene expression changes observed in the UC-phase 2 study.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>Integrated analyses across murine, patient-derived, and clinical trial datasets demonstrate conserved immune-epithelial responses to SIK2\/SIK3 inhibition by GLPG3970. These findings support the value of patient-relevant experimental platforms to assess target engagement and therapeutic activity prior to clinical testing, strengthening translational alignment in IBD drug development.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1093\/ecco-jcc\/jjag133","type":"journal-article","created":{"date-parts":[[2026,8,12]],"date-time":"2026-08-12T11:45:40Z","timestamp":1786535140000},"source":"Crossref","is-referenced-by-count":1,"title":["Bridging preclinical and clinical efficacy of SIK2\/SIK3 inhibition in inflammatory bowel disease through integrated murine, patient-derived models, and phase 2a trial-based analyses"],"prefix":"10.1093","volume":"20","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-8490-0150","authenticated-orcid":false,"given":"Lorenzo","family":"Giorio","sequence":"first","affiliation":[{"name":"Department of Chronic Diseases and Metabolism (CHROMETA), Translational Research Center for Gastrointestinal Disorders (TARGID), KU Leuven , Leuven,","place":["Belgium"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Steve","family":"De Vos","sequence":"additional","affiliation":[{"name":"Galapagos NV , Mechelen,","place":["Belgium"]},{"name":"FoxBioPath BV , Duffel,","place":["Belgium"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maikel Luis","family":"Colli","sequence":"additional","affiliation":[{"name":"Galapagos NV , Mechelen,","place":["Belgium"]},{"name":"Aspect Analytics NV , Genk,","place":["Belgium"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Didier","family":"Merciris","sequence":"additional","affiliation":[{"name":"Galapagos NV , Mechelen,","place":["Belgium"]},{"name":"In Vivo Pharmacology , Novalix, Romainville,","place":["France"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7709-3223","authenticated-orcid":false,"given":"Eva","family":"Vissers","sequence":"additional","affiliation":[{"name":"Department of Chronic Diseases and Metabolism (CHROMETA), Translational Research Center for Gastrointestinal Disorders (TARGID), KU Leuven , Leuven,","place":["Belgium"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2154-0490","authenticated-orcid":false,"given":"Tommaso","family":"Innocenti","sequence":"additional","affiliation":[{"name":"Department of Chronic Diseases and Metabolism (CHROMETA), Translational Research Center for Gastrointestinal Disorders (TARGID), KU Leuven , Leuven,","place":["Belgium"]},{"name":"Department of Experimental and Clinical Biomedical Sciences, University of Florence , Florence,","place":["Italy"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fabrice","family":"Kolb","sequence":"additional","affiliation":[{"name":"Galapagos NV , Mechelen,","place":["Belgium"]},{"name":"Coultreon Biopharma , Leuven,","place":["Belgium"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1492-0716","authenticated-orcid":false,"given":"Marc","family":"Ferrante","sequence":"additional","affiliation":[{"name":"Department of Chronic Diseases and Metabolism (CHROMETA), Translational Research Center for Gastrointestinal Disorders (TARGID), KU Leuven , Leuven,","place":["Belgium"]},{"name":"Department of Gastroenterology and Hepatology, University Hospitals Leuven, KU Leuven , Leuven,","place":["Belgium"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jo\u00e3o Guedelha","family":"Sabino","sequence":"additional","affiliation":[{"name":"Department of Chronic Diseases and Metabolism (CHROMETA), Translational Research Center for Gastrointestinal Disorders (TARGID), KU Leuven , Leuven,","place":["Belgium"]},{"name":"Department of Gastroenterology and Hepatology, University Hospitals Leuven, KU Leuven , Leuven,","place":["Belgium"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"S\u00e9verine","family":"Vermeire","sequence":"additional","affiliation":[{"name":"Department of Chronic Diseases and Metabolism (CHROMETA), Translational Research Center for Gastrointestinal Disorders (TARGID), KU Leuven , Leuven,","place":["Belgium"]},{"name":"Department of Gastroenterology and Hepatology, University Hospitals Leuven, KU Leuven , Leuven,","place":["Belgium"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0872-7776","authenticated-orcid":false,"given":"Kaline","family":"Arnauts","sequence":"additional","affiliation":[{"name":"Department of Chronic Diseases and Metabolism (CHROMETA), Translational Research Center for Gastrointestinal Disorders (TARGID), KU Leuven , Leuven,","place":["Belgium"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3898-7093","authenticated-orcid":false,"given":"Bram","family":"Verstockt","sequence":"additional","affiliation":[{"name":"Department of Chronic Diseases and Metabolism (CHROMETA), Translational Research Center for Gastrointestinal Disorders (TARGID), KU Leuven , Leuven,","place":["Belgium"]},{"name":"Department of Gastroenterology and Hepatology, University Hospitals Leuven, KU Leuven , Leuven,","place":["Belgium"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2026,9,11]]},"reference":[{"key":"2026091120022633800_jjag133-B1","doi-asserted-by":"publisher","first-page":"1507","DOI":"10.1053\/j.gastro.2021.09.078","article-title":"Breaking through the therapeutic ceiling: what will it take?","volume":"162","author":"Raine","year":"2022","journal-title":"Gastroenterology"},{"key":"2026091120022633800_jjag133-B2","doi-asserted-by":"publisher","first-page":"482","DOI":"10.1053\/j.gastro.2021.10.037","article-title":"Efficacy of biologic drugs in short-duration versus long-duration inflammatory bowel disease: a systematic review and an individual-patient data meta-analysis of randomized controlled trials","volume":"162","author":"Ben-Horin","year":"2022","journal-title":"Gastroenterology"},{"key":"2026091120022633800_jjag133-B3","doi-asserted-by":"publisher","first-page":"5233","DOI":"10.1021\/acs.jmedchem.3c02246","article-title":"Discovery of clinical candidate glpg3970: a potent and selective dual sik2\/sik3 inhibitor for the treatment of autoimmune and inflammatory diseases","volume":"67","author":"Peixoto","year":"2024","journal-title":"J Med Chem"},{"key":"2026091120022633800_jjag133-B4","doi-asserted-by":"publisher","first-page":"754","DOI":"10.3390\/ani9100754","article-title":"The 3Rs and humane experimental technique: Implementing change","volume":"9","author":"Hubrecht","year":"2019","journal-title":"Animals (Basel)"},{"key":"2026091120022633800_jjag133-B5","doi-asserted-by":"publisher","first-page":"e70195","DOI":"10.1002\/mco2.70195","article-title":"Organoid-guided precision medicine: From bench to bedside","volume":"6","author":"Tao","year":"2025","journal-title":"MedComm (2020)"},{"key":"2026091120022633800_jjag133-B6","doi-asserted-by":"publisher","first-page":"94","DOI":"10.1038\/s43586-022-00174-y","article-title":"Organoids","volume":"2","author":"Zhao","year":"2022","journal-title":"Nat Rev Methods Primers"},{"key":"2026091120022633800_jjag133-B7","doi-asserted-by":"publisher","first-page":"12020","DOI":"10.1038\/s41598-017-12222-9","article-title":"Ex vivo treatment of patient biopsies as a novel method to assess colorectal tumour response to the mek1\/2 inhibitor, selumetinib","volume":"7","author":"Novo","year":"2017","journal-title":"Sci Rep"},{"key":"2026091120022633800_jjag133-B8","doi-asserted-by":"publisher","first-page":"e0155335","DOI":"10.1371\/journal.pone.0155335","article-title":"Validation and optimization of an ex vivo assay of intestinal mucosal biopsies in crohn\u2019s disease: reflects inflammation and drug effects","volume":"11","author":"Vadstrup","year":"2016","journal-title":"PLoS One"},{"key":"2026091120022633800_jjag133-B9","doi-asserted-by":"publisher","first-page":"723","DOI":"10.1016\/j.tem.2018.08.004","article-title":"Salt-inducible kinases: physiology, regulation by camp, and therapeutic potential","volume":"29","author":"Wein","year":"2018","journal-title":"Trends Endocrinol Metab"},{"key":"2026091120022633800_jjag133-B10","doi-asserted-by":"publisher","first-page":"2231","DOI":"10.1152\/physrev.00023.2022","article-title":"The multiple roles of salt-inducible kinases in regulating physiology","volume":"103","author":"Jagannath","year":"2023","journal-title":"Physiol Rev"},{"key":"2026091120022633800_jjag133-B11","doi-asserted-by":"publisher","first-page":"12468","DOI":"10.1073\/pnas.1412308111","article-title":"Small-molecule screening identifies inhibition of salt-inducible kinases as a therapeutic strategy to enhance immunoregulatory functions of dendritic cells","volume":"111","author":"Sundberg","year":"2014","journal-title":"Proc Natl Acad Sci U S A"},{"key":"2026091120022633800_jjag133-B12","doi-asserted-by":"publisher","first-page":"711","DOI":"10.1189\/jlb.2A0715-307R","article-title":"Sik inhibition in human myeloid cells modulates TLR and IL-1R signaling and induces an anti-inflammatory phenotype","volume":"99","author":"Lombardi","year":"2016","journal-title":"J Leukoc Biol"},{"key":"2026091120022633800_jjag133-B13","doi-asserted-by":"publisher","first-page":"521","DOI":"10.1042\/BCJ20160646","article-title":"Inhibition of SIK2 and SIK3 during differentiation enhances the anti-inflammatory phenotype of macrophages","volume":"474","author":"Darling","year":"2017","journal-title":"Biochem J"},{"key":"2026091120022633800_jjag133-B14","doi-asserted-by":"publisher","DOI":"10.1172\/jci.insight.171776","article-title":"Selective SIK2\/SIK3 inhibition reprograms pro- and antiinflammatory pathways in myeloid cells, improving autoimmune disease outcomes","volume":"11","author":"De Vos","year":"2026","journal-title":"JCI Insight"},{"key":"2026091120022633800_jjag133-B15","author":"Galapagos","year":"2023"},{"key":"2026091120022633800_jjag133-B16","author":"Alvey","year":"2018"},{"key":"2026091120022633800_jjag133-B17","doi-asserted-by":"publisher","first-page":"1564","DOI":"10.1053\/j.gastro.2020.05.064","article-title":"Ex vivo mimicking of inflammation in organoids derived from patients with ulcerative colitis","volume":"159","author":"Arnauts","year":"2020","journal-title":"Gastroenterology"},{"key":"2026091120022633800_jjag133-B18","doi-asserted-by":"publisher","first-page":"228","DOI":"10.1016\/j.apsb.2021.04.007","article-title":"Targeting PDE4 as a promising therapeutic strategy in chronic ulcerative colitis through modulating mucosal homeostasis","volume":"12","author":"Li","year":"2022","journal-title":"Acta Pharm Sin B"},{"key":"2026091120022633800_jjag133-B19","doi-asserted-by":"publisher","first-page":"1517121","DOI":"10.3389\/fcell.2025.1517121","article-title":"Intestinal organoids in inflammatory bowel disease: advances, applications, and future directions","volume":"13","author":"Ren","year":"2025","journal-title":"Front Cell Dev Biol"},{"key":"2026091120022633800_jjag133-B20","doi-asserted-by":"publisher","first-page":"2014772","DOI":"10.1080\/19490976.2021.2014772","article-title":"Interleukin-1\u03b2 secretion induced by mucosa-associated gut commensal bacteria promotes intestinal barrier repair","volume":"14","author":"Wu","year":"2022","journal-title":"Gut Microbes"},{"key":"2026091120022633800_jjag133-B21","doi-asserted-by":"publisher","first-page":"1323865","DOI":"10.3389\/fphys.2023.1323865","article-title":"Club cell CREB regulates the goblet cell transcriptional network and pro-mucin effects of IL-1B","volume":"14","author":"Sponchiado","year":"2023","journal-title":"Front Physiol"},{"key":"2026091120022633800_jjag133-B22","doi-asserted-by":"publisher","first-page":"4433","DOI":"10.1172\/JCI125669","article-title":"IL-1\u03b2 dominates the promucin secretory cytokine profile in cystic fibrosis","volume":"129","author":"Chen","year":"2019","journal-title":"J Clin Invest"},{"key":"2026091120022633800_jjag133-B23","doi-asserted-by":"crossref","first-page":"497","DOI":"10.1016\/j.ebiom.2018.08.040","article-title":"Cox-2-PGE","volume":"36","author":"Li","year":"2018","journal-title":"EBioMedicine"},{"key":"2026091120022633800_jjag133-B24","doi-asserted-by":"publisher","first-page":"5","DOI":"10.15252\/embj.201694660","article-title":"Prostaglandin E2 promotes intestinal repair through an adaptive cellular response of the epithelium","volume":"36","author":"Miyoshi","year":"2017","journal-title":"Embo J"},{"key":"2026091120022633800_jjag133-B25","doi-asserted-by":"publisher","first-page":"36795","DOI":"10.1038\/srep36795","article-title":"PGE2 is a direct and robust mediator of anion\/fluid secretion by human intestinal epithelial cells","volume":"6","author":"Fujii","year":"2016","journal-title":"Sci Rep"},{"key":"2026091120022633800_jjag133-B26","doi-asserted-by":"publisher","first-page":"507","DOI":"10.1016\/j.jcmgh.2019.11.008","article-title":"Human colon-on-a-chip enables continuous in vitro analysis of colon mucus layer accumulation and physiology","volume":"9","author":"Sontheimer-Phelps","year":"2020","journal-title":"Cell Mol Gastroenterol Hepatol"},{"key":"2026091120022633800_jjag133-B27","doi-asserted-by":"publisher","first-page":"175","DOI":"10.1093\/ecco-jcc\/jjad142","article-title":"Definitions of histological abnormalities in inflammatory bowel disease: an ECCO position paper","volume":"18","author":"Feakins","year":"2024","journal-title":"J Crohns Colitis"},{"key":"2026091120022633800_jjag133-B28","doi-asserted-by":"publisher","first-page":"1574","DOI":"10.1111\/apt.16083","article-title":"Evaluating the optimum number of biopsies to assess histological inflammation in ulcerative colitis: a retrospective cohort study","volume":"52","author":"Battat","year":"2020","journal-title":"Aliment Pharmacol Ther"},{"key":"2026091120022633800_jjag133-B29","doi-asserted-by":"publisher","first-page":"e70013","DOI":"10.1002\/eji.70013","article-title":"Ex vivo modeling and pharmacological modulation of tissue immune responses in inflammatory bowel disease using precision-cut intestinal slices","volume":"55","author":"Grieger","year":"2025","journal-title":"Eur J Immunol"},{"key":"2026091120022633800_jjag133-B30","doi-asserted-by":"publisher","first-page":"511","DOI":"10.1038\/s43588-021-00114-y","article-title":"The inflammatory bowel disease transcriptome and metatranscriptome meta-analysis (IBD TAMMA) framework","volume":"1","author":"Massimino","year":"2021","journal-title":"Nat Comput Sci"},{"key":"2026091120022633800_jjag133-B31","doi-asserted-by":"publisher","first-page":"1029","DOI":"10.2147\/JIR.S288280","article-title":"Metalloproteinases in inflammatory bowel diseases","volume":"14","author":"Mar\u00f4nek","year":"2021","journal-title":"J Inflamm Res"},{"key":"2026091120022633800_jjag133-B32","doi-asserted-by":"publisher","first-page":"3339","DOI":"10.3748\/wjg.v19.i21.3339","article-title":"Gene expression profiles in peripheral blood mononuclear cells of ulcerative colitis patients","volume":"19","author":"Miao","year":"2013","journal-title":"World J Gastroenterol"},{"key":"2026091120022633800_jjag133-B33","doi-asserted-by":"publisher","first-page":"301","DOI":"10.1016\/bs.apha.2024.10.010","article-title":"The potential of targeting TREM-1 in IBD","volume":"101","author":"Vinolo","year":"2024","journal-title":"Adv Pharmacol"},{"key":"2026091120022633800_jjag133-B34","doi-asserted-by":"crossref","DOI":"10.1093\/ecco-jcc\/jjae117","article-title":"Discordant effects of janus kinase inhibition ex vivo on inflammatory responses in colonic compared to ileal mucosa","volume":"19","author":"Kaboub","year":"2025","journal-title":"J Crohns Colitis"},{"key":"2026091120022633800_jjag133-B35","author":"Therapeutics","year":"2025"},{"key":"2026091120022633800_jjag133-B36","author":"Zhang LC","year":"2026"},{"key":"2026091120022633800_jjag133-B37","author":"Daigle LC","year":"2026"}],"container-title":["Journal of Crohn's and Colitis"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/ecco-jcc\/article-pdf\/20\/9\/jjag133\/71034743\/jjag133.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/ecco-jcc\/article-pdf\/20\/9\/jjag133\/71034743\/jjag133.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,9,12]],"date-time":"2026-09-12T00:02:32Z","timestamp":1789171352000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/ecco-jcc\/article\/doi\/10.1093\/ecco-jcc\/jjag133\/8790823"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,9]]},"references-count":37,"journal-issue":{"issue":"9","published-print":{"date-parts":[[2026,9,3]]}},"URL":"https:\/\/doi.org\/10.1093\/ecco-jcc\/jjag133","relation":{},"ISSN":["1873-9946","1876-4479"],"issn-type":[{"value":"1873-9946","type":"print"},{"value":"1876-4479","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2026,9]]},"published":{"date-parts":[[2026,9]]},"article-number":"jjag133"}}